Events

#Events #Neuroscience #Society for Neuroscience

Looking forward to SfN’s Neuroscience 2024

Ahead of the Society for Neuroscience's (SfN) Neuroscience 2024 in Chicago, US from 5-9 October, DDW’s Megan Thomas, speaks to SfN President Dr Marina Picciotto, and looks at what we can expect from this annual global neuroscience event.  SfN perspective Dr Marina Picciotto reflects that the SfN annual meeting started… Read More

#Exclusive Content

Lab technology and automation
#ELRIG #Events

What to expect from Drug Discovery 2024

Diana Spencer reveals what will be on offer at Drug Discovery 2024, including DDW's new research and consultancy service. With a theme of ‘connecting minds, transforming science, empowering the community’, Drug Discovery 2024 will take place 2-3 October 2024 at the Excel in London, UK. This year, the event will… Read More

#Exclusive Content

The Royal College of Physicians Edinburgh
#Drug discovery #ELRIG #Events #Scotland

Drug discovery innovation in Scotland, the home of invention

Diana Spencer reports on ELRIG UK’s Drug Discovery in Scotland Forum, held in the grandiose surroundings of the Royal College of Physicians Edinburgh in September. The Drug Discovery in Scotland Forum showcased how Scotland is shaping drug discovery using approaches including traditional small molecules, therapeutic proteins, CRISPR/ RNAi and cell… Read More

#Exclusive Content

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News

Conference microphone
#Charles River #Events #UK

Charles River hosts drug discovery seminars

Charles River Laboratories is hosting two drug discovery seminars in the UK in September. The first will be in Cambridge on 25 September covering drug discovery capabilities, with the second at the company’s Portishead, UK site covering immuno-oncology, infectious disease capabilities on 26 September. Read More

#News

Events
#ASGCT #Blood donation #Drug delivery #Drug discovery #Events #ISCT #Pharma Sustainability Integrates #Synthetic & Engineering Biology British-Swiss Summit

Event highlights in 2024 so far  

There have been a number of key events in the drug discovery community’s diary in 2024 to date, from AACR 2024 and LSX Congress 2024 to SLAS 2024 in Boston and Barcelona. DDW’s Sarah Orme reflects on other significant events in the year to date.   Pharma Sustainability Integrates 2024   On… Read More

#Exclusive Content

Fibroblast growth factor receptor 3
#Events #Gene mutation #Preclinical investigations #Tyra Biosciences

Preclinical tests support FGFR3 inhibitor in skeletal dysplasia

Biotechnology company Tyra Biosciences has announced preclinical proof-of-concept results with TYRA-300, an investigational oral fibroblast growth factor receptor 3 (FGFR3) selective inhibitor, in hypochondroplasia (HCH). The results were presented at the 6th Annual Achondroplasia & Skeletal Dysplasia Research Conference (Pharmachon 2024). HCH is a… Read More

#News

Autoantibodies bond to receptor (achr) blocking the acetylcholine transmitters in Myasthenia gravis (MG).
#Antibody Fragments #argenx #Autoimmune disease #Events #Neurology

Antibody fragment shows promise in myasthenia gravis

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting. In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a… Read More

#News

#Drug discovery #ELRIG #Events #The Protein Society

Partnership to advance protein sciences in drug discovery 

ELRIG UK has partnered with The Protein Society (TPS) to provide forums for the advancement of research into protein structure, function, design and applications.   The partners will collaborate to deliver a joint conference on ‘Protein Sciences in Drug Discovery’, bringing together their respective communities to focus on… Read More

#News

Immune thrombocytopenia test
#Events #ITP #Monoclonal antibodies #Phase II trial #Takeda

Favourable results for mAb in bleeding disorder shared at ISTH

Takeda has shared positive results from its Phase IIb study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterised by the accelerated destruction of platelets in blood, resulting… Read More

#News

Woman with a nose bleed
#Bispecific Antibodies #Events #Haemophilia #Novo Nordisk #Phase III trial

Bispecific antibody successfully reduced bleeds in haemophilia A

Novo Nordisk has announced results from the Phase III FRONTIER2 trial of 254 adults and adolescents aged 12 years and over with haemophilia A, with and without inhibitors. The trial assessed both once-weekly and once-monthly prophylactic treatment with the investigational treatment Mim8. The data… Read More

#News

#American Diabetes Association #Diabetes #Events #GLP-1 #Obesity #Weight loss

New evidence on GLP-1 receptor agonists at ADA 2024

Further insights on glucagon-like peptide-1 (GLP-1) receptor agonists were presented at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida, 21-24 June. Obesity affects 41.9% of adults and 19.7% of children and adolescents in the US, and 90% of people with diabetes also live… Read More

#News #Trending News

Blood cancer
#Antibodies #Blood cancer #CAR-T #Cell therapy #Clinical trials #Events #Haematology

EHA2024: Industry shares latest drug research in blood cancers

A number of key findings in haematological malignancies were revealed at this year’s European Hematology Association (EHA) Congress, which was held in Madrid, Spain 13-16 June. Ibrutinib and talquetamab, Johnson & Johnson Johnson & Johnson shared clinical trial results for its drug candidates Talvey (talquetamab) and… Read More

#Cancer Research #News #Trending News

Conference speaker
#ASCO #Clinical trials #Drug discovery #Events #Oncology #Preclinical investigations

ASCO 2024 research highlights

As well as key findings with regards to lorlatinib for lung cancer, epcoritamab in follicular lymphoma, and pembrolizumab for bowel cancer, there were other significant study results revealed at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. RP1 and RP2 for melanoma… Read More

#Cancer Research #News #Trending News

Barcelona skyline
#Events #Lab automation #Lab technology #SLAS Europe

SLAS Europe reveals New Product Award finalists

SLAS has announced the finalists for its New Product Award, with the winners to be announced at the annual conference. The SLAS 2024 Europe Conference and Exhibition is heading back to Barcelona, 27-29 May, for its fifth annual European conference. It will feature scientific… Read More

#News